Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM. 2. Juni 2012 Hadji, P., Kieback, D.G., Tams, J., Hasenburg, A., Ziller, M., 2012. Ann Oncol 23, 2566–2572. doi:10.1093/annonc/mds055. Abstract Effects of exemestane and tamoxifen on hormone levels within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German substudy. Hadji, P., Kauka, A., Bauer, T., Tams, J., Hasenburg, A., Kieback, D.G., 2012. Climacteric 15, 460–466. doi:10.3109/13697137.2011.647839 Abstract… Weiterlesen Erneute Anti-HER2-Therapie mit Herceptin® beim ersten Rezidiv des HER2-positiven Mammakarzinoms-1. Interimsanalyse der nichtinterventionellen Studie (NIS) ML21589. Hanker, L., Prange-Krex, G., Janssen, J., Reichert, D., Schröder, J., Förster, F., Schnohr, S., Hitschold, T., Indorf, M., Kaufmann, M., 2012. Senologie 9(02). doi:10.1055/s-0032-1313426… Weiterlesen